SUN-TIMES MEDIA September 27, 2012 6:58PM

Updated: September 28, 2012 3:00AM

Abbott Laboratories gave incorrect education credentials for the executive chosen to lead its pharmaceutical spinoff in regulatory filings between 2002 and 2007, Crains Chicago Business is reporting.

Richard A. Gonzalez, named CEO of AbbVie, did not receive a biochemistry bachelors degree nor a biochemistry masters degree from the universities Abbott filings listed, Crains reported.

According to Crains, Gonzalez did not receive a bachelors degree in biochemistry from the University of Houston, nor a masters degree in biochemistry from the University of Miami, contrary to claims in Abbotts filings with the U.S. Securities and Exchange Commission when the longtime company executive was a director.

He started at the company in 1977 and retired from Abbott as president and chief operating officer in 2007, but returned two years later.

Gonzalez, 58, currently executive vice president, Global Pharmaceuticals at Abbott, was chosen to be chairman and CEO of AbbVie (pronounced Abb-vee), the new research-based pharmaceutical firm, which is projected to have $18 billion in annual sales after it is spun off later this year.

Abbott external communications Vice President Melissa Brotz confirmed to Crains that Gonzalez did not receive degrees from either university.

The inaccurate information about his education was included in SEC filings as a result of an internal administrative error. She told Crains that Abbott learned about the errors some time ago. The company corrected the information on its Web site immediately after the errors were discovered, she said.

According to the companys Web site, Gonzalez is listed as a research biochemist at the University of Miami School of Medicine and attended the University of Houston, majoring in biochemistry,

Read the original:
CEO of Abbott spinoff lacks degrees claimed in filings